Entopsis has announced that it will pursue strategic alternatives for its OpsisDx urine-based technology platform that offers a diagnostic test for detecting early-stage cancers.
The company said it has engaged with Berkery Noyes as its financial advisor to assist in the endeavor. OpsisDx detects urine chemical signatures through a proprietary array and delivers results via the company's machine-learning algorithms.
Entopsis said validation studies on OpsisDx initially focused on detecting early-stage cancers, and the platform has now expanded to detect multiple other diseases.
